PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsSulbactam
Sulbactam
Ampicillin / Sulbactam, Unasyn, Xacduro (sulbactam) is a small molecule pharmaceutical. Sulbactam was first approved as Unasyn on 1986-12-31. It is used to treat acinetobacter infections, bacterial skin diseases, escherichia coli infections, intraabdominal infections, and klebsiella infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Combinations
Ampicillin sulbactam, Unasyn, Xacduro (discontinued: Ampicillin sulbactam, Unasyn)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ampicillin sodium
+
Sulbactam sodium
Tradename
Company
Number
Date
Products
UNASYNPfizerN-050608 RX1986-12-31
3 products, RLD, RS
Show 1 discontinued
Durlobactam sodium
+
Durlobactam sodium
+
Sulbactam sodium
Tradename
Company
Number
Date
Products
XACDURO (COPACKAGED)Entasis TherapeuticsN-216974 RX2023-05-23
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
ampicillin and sulbactamANDA2024-10-17
ampicillin sodium and sulbactam sodiumANDA2024-10-28
unasynNew Drug Application2024-10-15
xacduroNew Drug Application2023-09-12
Agency Specific
FDA
EMA
Expiration
Code
DURLOBACTAM SODIUM / DURLOBACTAM SODIUM / SULBACTAM SODIUM, XACDURO (COPACKAGED), ENTASIS THERAP
2033-05-23GAIN
2028-05-23NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Durlobactam Sodium / Durlobactam Sodium / Sulbactam Sodium, Xacduro (Copackaged), Entasis Therap
99685932035-11-17DPU-2840
103764992035-11-17DPU-2840
93092452033-04-02DP
96230142033-04-02U-2840
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01C: Beta-lactam antibacterials, penicillins
— J01CG: Beta-lactamase inhibitors, systemic penicillins
— J01CG01: Sulbactam
HCPCS
Code
Description
J0295
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm
Clinical
Clinical Trials
58 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—32312424
Communicable diseasesD003141———229417
PneumoniaD011014EFO_0003106—1154313
Urinary tract infectionsD014552EFO_0003103N39.0—21328
Respiratory tract infectionsD012141—J06.9—1—326
BacteremiaD016470EFO_0003033R78.81——1124
SepsisD018805HP_0100806A41.9——21—3
Surgical wound infectionD013530————12—3
Environmental biomarkersD000074062————11—2
Wound infectionD014946—————112
Show 27 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PyelonephritisD011704EFO_1001141N10-N16—11——2
Bacterial pneumoniaD018410EFO_1001272J15.9——2——2
AbscessD000038EFO_0003030———1—12
Lung abscessD008169EFO_1001362J85.2——1—12
MortalityD009026EFO_0004352———1——1
InflammationD007249MP_0001845———1——1
Iatrogenic diseaseD007049————1——1
Aspiration pneumoniaD011015EFO_1001399J69.0——1——1
ChorioamnionitisD002821—O41.12—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cleft palateD002972HP_0000175Q35—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteomyelitisD010019EFO_0003102M861————1
Jaw fracturesD007572——1————1
Mandibular fracturesD008337—S02.61————1
Renal insufficiencyD051437HP_0000083N191————1
Healthy volunteers/patients———1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PeritonitisD010538EFO_0008588K65————22
Critical illnessD016638——————11
Asymptomatic infectionsD058345——————11
BacteriuriaD001437—R82.71————11
Healthcare-associated pneumoniaD000077299——————11
AppendicitisD001064EFO_0007149K37————11
Abdominal abscessD018784EFO_1001753—————11
GranulomaD006099——————11
Pilonidal sinusD010864HP_0010769L05————11
Escherichia coli infectionsD004927EFO_1001318B96.20————11
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSulbactam
INNsulbactam
Description
Sulbactam is a member of penicillanic acids.
Classification
Small molecule
Drug classbeta-lactamase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
Identifiers
PDB—
CAS-ID68373-14-8
RxCUI—
ChEMBL IDCHEMBL403
ChEBI ID9321
PubChem CID130313
DrugBank—
UNII IDS4TF6I2330 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Xacduro – Innoviva
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Sulbactam
+
Ampicillin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 18,148 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,320 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use